ABT · News · 20260930N

Revenue Performance and Mix

ABBOTT LABORATORIES · 2026-09-30 · Importance 50 · Surprise 42 · In source text

Abbott reported second-quarter 2026 revenue of $12.59 billion, exceeding analyst expectations. Adjusted EPS was $1.31 for the quarter, also above expectations. Abbott raised its full-year 2026 adjusted EPS guidance to $5.45–$5.60 and scheduled its next earnings report for October 20, 2026.

Key facts

• Abbott reported Q2 2026 adjusted EPS of USD 1.31 and revenue of USD 12.59 billion. source
• A report stated Abbott Laboratories' stock price has fallen 22.9% over the past year and the article referenced a current share price of $100.95. source
• A report stated Abbott Laboratories' latest trading day saw the stock settle at $98.83, representing a -2.1% change from its previous close. source
• Abbott Laboratories stock showed a pre-market gain of 0.48 percent, trading at EUR 89.14 on September 30, 2026, following the prior close of EUR 88.71. source
• A news item reported Abbott Laboratories stock was trading at EUR 88.79 after reporting Q2 results. source
• Grace Groner invested $180 in Abbott Laboratories stock in 1935 and by her death in 2010 her estate was valued at approximately $7 million. source

Impact estimates